The Indian Pharmaceutical Market - Leading Domestic Companies 2015

Publisher Name :
Date: 14-Sep-2015
No. of pages: 152

This report discusses the Indian pharmaceutical industry in depth, with specific focus on the ten leading domestic India pharmaceutical companies; their key financials since FY2011; their key global markets; their Merger, Acquisition and Joint Venture activity; their Research & Development spending; as well as Strength, Weakness, Opportunity and Threats that each individual company faces. This report also offers a snapshot of the key financials in the India pharmaceutical sector; import / export values, and where the India based pharmaceutical companies are generating their revenue globally. The report concludes with interviews with directors of Ipca Laboratories, Cadila Healthcare and Cipla.

The Indian Pharmaceutical Market - Leading Domestic Companies 2015 also highlights what drives, or restrains, the market for these leading companies;

Key Drivers

- US Generics Market

- JV, Acquisitions & Mergers

- Patent Cliff

- Increased Domestic Health Spending

- Geographic Expansion into Semi-Regulated and Emerging Pharma Markets

- Economies in Drug Production/Manufacture

- Governmental Support

Key Restraints

- Industry Inefficiencies

- Regulatory Non-Compliance

- Price Ceilings

- Intellectual Property Rights / Compulsory Licence

- Inadequate Health Insurance, India

The US generics market has been a massive growth driver for the India pharmaceutical market, with many leading companies in GMR Data's list generating over 50% of their annual revenues from the US generics market. However with access to the US market comes increased scrutiny from the US FDA; nearly all the companies in the top ten have faced warnings from the FDA; ranging from minor procedural infractions to complete manufacturing shutdown.

The report contains over 130 tables & figures across 152 pages and concludes with 3 exclusive interviews with managing directors of 3 leading Indian pharmaceutical companies;

- Cipla

- Cadila Healthcare

- IPCA Laboratories

Companies Mentioned

- Abbott

- AbbVie

- Actelion

- Agila Specialities

- Amgen

- Amgen

- ANVISA Brazil

- Apotex Inc

- Aptil Pharma Limited

- Arab Company for Drug Industries and Medical Appliances

- AstraZeneca

- AstraZeneca Pharma India Limited (AZPIL)

- BASF

- Bayer Healthcare

- Bayer Zydus Pharma

- Betapharm

- Biocon

- Biopharm SPA

- Bristol- Myers Squibb (BMS)

- Cadila Healthcare

- Capital Advisory Group

- Caraco

- Celeris

- Celon Laboratories

- Center of Excellence for Inhalation Research

- Chattem

- Cipla Ltd

- Cipla Medpro

- Claris Lifesciences

- CP Pharmaceuticals

- Curatio Healthcare

- Daiichi Sankyo

- Dishman Pharmaceuticals & Chemicals

- Dr Reddy's Laboratories Ltd.

- Dumex

- Duomed Produtos Farmaceuticos

- DUSA

- Elder Pharmaceuticals Ltd

- Endo Pharmaceuticals

- Espharma GmbH

- Farma World Importacao e Exportacao de Medicamentos LTDA

- Fleming Labs

- Fujifilm Diosynth Bio technologies

- GAVIS Pharmaceuticals LLC

- Generica KG Germany

- Gilead Sciences Inc.

- GlaxoSmithKline (GSK)

- Glenmark Generics Ltd.

- Glenmark Pharmaceuticals Ltd.

- Health Canada

- Heumann Pharma GmbH & Co.

- Heunet Pharma GmbH Germany

- Hospira

- India Department of Industrial Policy and Promotion (DIPP)

- India Planning Commission

- Indian Ministry of Chemicals and Fertilizers

- Insurance Regulatory and Development Authority of India

- International Diabetes Federation (IDF)

- IPCA Laboratories

- IsoRay

- Janssen Pharmaceutica N.V.

- Japan PMDA

- Jubilant Biosys Pte. Ltd.

- Jubilant Cadista Pharmaceuticals Inc.

- Jubilant Discovery Services Inc.

- Jubilant HollisterStier General Partnership

- Jubilant Life Sciences

- Jubilant Life Sciences (Shanghai) Limited

- Jubilant Life Sciences (USA) Inc.

- Laboratories Grin S.A. de C.V.

- Laboratorios Combix S.L

- Laboratorios Torrent (Malaysia) SDN.BHD. Malaysia

- Laboratorios Torrent, S.A. de C.V. Mexico

- Litha

- Lupin Ltd

- MCC South Africa

- Medicamenta a.s

- Medicine San Frontier

- Medpro Pharmaceutica (Pty) Ltd

- Medquímica Indústria Farmacêutica S.A.,

- Merck Serono

- Merind

- Mnemosyne Pharma. Inc.

- Multicare Pharmaceuticals

- Mylan

- Nanomi BV

- Natco Pharma

- National Pharmaceutical Pricing Authority (NPPA)

- Natrol

- Negma,

- Nesher Pharmaceuticals

- Norispharm GmbH Germany

- Novartis

- Novel Laboratories Inc.

- OctoPlus

- Orchid Chemicals

- Organisation for Economic Co-operation and Development (OECD)

- Organisation of the Pharmaceutical Producers of India (OPPI)

- Orion Corp.

- Oscient Pharmaceuticals

- Otsuka Pharmaceutical Co., Ltd

- Panacea Biotec Ltd

- Pfizer

- Pharma Dynamics

- Pinewood Laboratory

- Piramal

- PromiusPharma

- Ranbaxy

- Roche

- S&D Pharma

- Salix Pharmaceuticals

- Sanofi

- Societe Marocaine De Cooperation Pharmaceutique

- Spimaco

- Strides Arcolab Ltd

- Sun Pharmaceutical Industries Ltd

- Taro

- Temmler Pharma GMBH & Co

- The Pharmaceutical Institute (PHI).

- Torrent Australasia Pty Ltd. Australia

- Torrent Do Brasil Ltda Brazil

- Torrent Pharma (Thailand) Co., Limited. Thailand

- Torrent Pharma (UK) Ltd (TPUK) United Kingdom

- Torrent Pharma Canada Inc. Canada

- Torrent Pharma France S.A.S. France

- Torrent Pharma GmbH (TPG) Germany

- Torrent Pharma Inc. USA

- Torrent Pharma Philippines Inc. Philippines

- Torrent Pharma S.R.L. Romania

- Torrent Pharmaceuticals Limited

- UK Medicines & Healthcare products Regulatory Agency (UK MHRA / MHRA)

- URL Pharma

- US Federal Trade Commission

- US Food & Drug Administration (USFDA / FDA)

- Wallis Laboratory

- Wockhardt Limited

- World Bank

- World Health Organisation (WHO)

- World Trade Organization

- Yoshindo Inc.

- Zao Torrent Pharma Russia

- Zydus BSV Pharma Pvt. Ltd.

- Zydus Cadila

- Zydus Cadila Healthcare Ltd

- Zydus Discovery DMCC

- Zydus Hospira Oncology Pvt. Ltd.

- Zydus Takeda Healthcare Pvt. Ltd.

- Zydus Worldwide DMCC

- Zyg Pharma Private Limited

The Indian Pharmaceutical Market - Leading Domestic Companies 2015

Table of Contents

1 Executive Summary
1.1 Executive Summary
1.2 Research and Analysis Methods
1.3 Drivers & Restraints
1.3.1 Drivers
1.3.1.1 US Generics Market
1.3.1.2 JV, Acquisitions & Mergers
1.3.1.3 Patent Cliff
1.3.1.4 Increased Domestic Health Spending
1.3.1.5 Geographic Expansion into Semi-Regulated and Emerging Pharma Markets
1.3.1.6 Economies in Drug Production/Manufacture
1.3.1.7 Governmental Support
1.3.2 Restraints
1.3.2.1 Industry Inefficiencies and Regulatory Non-Compliance
1.3.2.2 Price Ceilings
1.3.2.3 Intellectual Property Rights / Compulsory Licence
1.3.2.4 Inadequate Health Insurance, India
2 Indian Pharmaceutical Market Overview
2.1 Evolution of the India Pharmaceutical Sector
2.1.1 Key Reforms/Regulations
2.1.2 Customers/End-Users
2.1.3 Pricing/Reimbursement
2.1.4 Competitive Landscape
3 India Pharmaceutical Market Revenue
3.1 Pharmaceutical Market Revenue - Domestic
3.2 Pharmaceutical Market Revenue - Export
3.3 Domestic Pharmaceutical Drugs Market Share
4 - The 10 Leading Indian Pharmaceutical Companies 2015
4.0.1 The Top Ten India Pharmaceutical Companies FY2015, by Revenue
4.0.2 The Top Ten Domestic & Foreign Revenue Generators FY2015
4.0.3 The Top Ten R&D Spending FY2015
4.1 Sun Pharmaceutical Industries Ltd
4.1.1 Sun Pharma Company Profile
4.1.2 Sun Pharma Financial Analysis
4.1.3 Sun Pharma SWOT Analysis
4.1.3.1 Strengths
4.1.3.1.1 Robust R&D Spending
4.1.3.1.2 Strong Drugs Pipeline
4.1.3.1.3 Strong Position in Key Markets
4.1.3.2 Weaknesses
4.1.3.2.1 Export Dependency
4.1.3.3 Opportunities
4.1.3.3.1 Capitalisation on the Ranbaxy Acquisition
4.1.3.3.2 Further Acquisition
4.1.3.4 Threats
4.1.3.4.1 FDA warnings
4.1.3.4.2 Ranbaxy Merger Issues
4.2 Dr Reddy's Laboratories Ltd.
4.2.1 Dr Reddy's Company Profile
4.2.2 Dr Reddy's Financial Analysis
4.2.3 Dr Reddy SWOT Analysis
4.2.3.1 Strengths
4.2.3.1.1 Global Presence through Strategic Acquisitions and Partnerships
4.2.3.1.2 Generic Sales in Key Geographies
4.2.3.1.3 Strong Operational Infrastructure and Robust Base for Research
4.2.3.2 Weaknesses
4.2.3.2.1 Increased R&D spending to put Pressures on Margins
4.2.3.3 Opportunities
4.2.3.3.1 Growth in US Generic Market
4.2.3.3.2 Biosimilars Market Opportunity
4.2.3.4 Threats
4.2.3.4.1 Economic / Political Uncertainties in Some Markets
4.2.3.4.2 Manufacturing Issues Leading to FDA Scrutiny / Drug Recalls
4.3 Lupin Ltd
4.3.1 Lupin Company Profile
4.3.2 Lupin Financial Analysis
4.3.3 Lupin SWOT Analysis
4.3.3.1 Strengths
4.3.3.1.1 Strong US Presence
4.3.3.1.2 Diverse ROW Sales Revenue
4.3.3.1.3 Acquisitions / JVs
4.3.3.2 Weaknesses
4.3.3.2.1 Net Exporter
4.3.3.3 Opportunities
4.3.3.3.1 Japan
4.3.3.3.2 Anti-TB Market
4.3.3.4 Threats
4.3.3.4.1 Consolidation in the US Pharmaceutical Industry
4.4 Cipla Ltd
4.4.1 Cipla Company Profile
4.4.2 Cipla Financial Analysis
4.4.3.1 Strengths
4.4.3.1.1 Global Presence
4.4.3.1.2 Numerous Global JVs/Acquisitions
4.4.3.1.3 R&D Focus
4.4.3.2 Weaknesses
4.4.3.2.1 Robust Competition
4.4.3.3 Opportunities
4.4.3.3.1 Focus on Key Markets
4.4.3.3.2 Successful Launch of Late Stage Pipeline
4.4.3.3.3 Investment in MMV
4.4.3.4 Threats
4.4.3.4.1 FDA Approval
4.4.3.4.2 Domestic Pricing Regulations
4.5 Zydus Cadila Healthcare Ltd
4.5.1 Cadila Company Profile
4.5.2 Cadila Financial Analysis
4.5.3 Cadila SWOT Analysis
4.5.3.1 Strengths
4.5.3.1.1 Drug Approval History
4.5.3.1.2 Solid Platforms in Key Markets
4.5.3.1.3 JVs, Alliances & Subsidiaries
4.5.3.2 Weaknesses
4.5.3.2.1 Delays in Approval
4.5.3.2.2 Price Controls
4.5.3.3 Opportunities
4.5.3.3.1 R&D Strength
4.5.3.3.2 Opportunities to Strengthen their Global Markets
4.5.3.4 Threats
4.5.3.4.1 Further FDA Warnings
4.6 Aurobindo Pharma Limited
4.6.1 Aurobindo Company Profile
4.6.2 Aurobindo Financial Analysis
4.6.3 Aurobindo SWOT Analysis
4.6.3.1 Strengths
4.6.3.1.1 Acquisitions / JVs
4.6.3.1.2 Sales from both Domestic & Global Market
4.6.3.1.3 Strong in-house R&D Base
4.6.3.2 Weaknesses
4.6.3.2.1 Unscheduled Changes in Management
4.6.3.3 Opportunity
4.6.3.3.1 Strength of Approved Fillings, Internationally
4.6.3.3.2 Strong Pipeline
4.6.3.3.3 Geographical Growth
4.6.3.4 Threats
4.6.3.4.1 Competition
4.6.3.4.2 Regulatory & Compliance Risks
4.6.3.4.3 Pricing risks
4.7 Glenmark Pharmaceuticals Ltd.
4.7.1 Glenmark Company Profile
4.7.2 Glenmark Financial Analysis
4.7.3 Glenmark SWOT Analysis
4.7.3.1 Strengths
4.7.3.1.1 Strong R&D Base
4.7.3.1.2 Revenue from Multiple Markets
4.7.3.2 Weakness
4.7.3.2.1 Organic Growth
4.7.3.3 Opportunities
4.7.3.3.1 Continued Growth in Global Markets
4.7.3.4 Threats
4.7.3.4.1 Litigation
4.8 Jubilant Life Sciences
4.8.1 Jubilant Company Profile
4.8.2 Jubilant Financial Analysis
4.8.3.1 Strengths
4.8.3.1.1 Attracts Foreign Investment
4.8.3.1.2 Multiple Global Production Bases
4.8.3.2 Weaknesses
4.8.3.2.1 R&D Effectiveness
4.8.3.3 Opportunities
4.8.3.3.1 Expanding Global Drugs Pipeline
4.8.3.3.2 Geographical Expansion
4.8.3.3.3 Significant Subsidiaries / Collaborations
4.8.3.4 Threats
4.8.3.4.1 Rising Raw Material Prices
4.9 Torrent Pharmaceuticals Limited
4.9.1 Torrent Company Profile
4.9.2 Torrent Financial Analysis
4.9.3 Torrent SWOT Analysis
4.9.3.1 Strengths
4.9.3.1.1 Revenue Generated in Diverse Geographical Markets
4.9.3.1.2 Integration of Elder Pharma
4.9.3.2 Weaknesses
4.9.3.2.1 R&D Spending
4.9.3.3 Opportunities
4.9.3.3.1 Growth in Torrent's Global Markets
4.9.3.3.2 Global Drugs Pipeline
4.9.3.4 Threats
4.9.3.4.1 Drug Price Controls
4.9.3.4.2 Litigation
4.10 Wockhardt Limited
4.10.1 Wockhardt Company Profile
4.10.2 Wockhardt Financial Analysis
4.10.3 Wockhardt SWOT Analysis
4.10.3.1 Strengths
4.10.3.1.1 R&D Spending
4.10.3.1.2 Multiple Markets Generating Revenue
4.10.3.2 Weaknesses
4.10.3.2.1 Regulatory Warnings
4.10.3.2.2 US Sales Growth
4.10.3.3 Opportunity
4.10.3.3.1 Further M&A
4.10.3.4 Threat
4.10.3.4.1 Increased Regulatory Scrutiny
5 Expert Opinion
5.1 Cipla Ltd
5.2 Cadila Healthcare
5.3 IPCA Laboratories

List of Tables

Table 1.1 Total Revenue for Ten Leading Indian Pharmaceutical Companies FY2015 ($/m)
Table 1.3.1 Drivers and Restraints of the Leading Domestic Companies in the India Pharmaceutical Market
Table 1.3.2 Indian Pharmaceutical Companies M&A /JV Activity
Table 1.3.3 High Earning Drugs Scheduled to Exit US Patent to 2016 ($/bn)
Table 1.3.4 India GDP & Healthcare Spending, 2013 ($/bn)
Table 1.3.5 Forecast of Public Vs Private Healthcare Spending, India 2005 -2020 ($/bn, %)
Table 1.3.6 Key Adult Health Risk Factors, India, 2013
Table 1.3.7 Diabetes Population, Prevalence and Healthcare Expenditure, India, 2013 ($)
Table 1.3.8 Forecast of Population & GDP Growth, India 1990-2020 ($ & %)
Table 1.3.9 Examples of Indian & Foreign Pharmaceutical Companies Partnerships 2009 - 2014
Table 1.3.10 Japanese Companies Investments in India Pharmaceutical Companies 2008-2012 ($)
Table 2.1 Multinational Vs Domestic Companies Pharmaceutical Market Dominance 1952-2000
Table 2.2 Rural Vs Urban Hospital & Doctor Ratios, India, 2014
Table 2.3 Healthcare Expenditure - Reimbursement Source India, 2014
Table 2.4 Comparative Analysis - Healthcare Expenditure, India Vs Global, 2014 ($)
Table 3.1 Pharmaceutical Market Revenue India 2005-2015 ($/bn)
Table 3.2 Export Revenue by Geographical Region 2011-2015 ($/m)
Table 3.3 Pharmaceutical Market Revenue India 2005-2015 ($/bn)
Table 3.4 Indian Pharmaceutical Market - Products Market Share, 2015 (%)
Table 4.0.1 Top 10 Indian Pharmaceutical Companies, by Revenue, FY2015 ($/m)
Table 4.0.2 Top 10 Indian pharmaceutical Companies by Domestic & Foreign Revenue FY2015 ($/m)
Table 4.0.3 Top 10 Indian Pharmaceutical Companies R&D Spending, FY2015 ($/m)
Table 4.1.1 Sun Pharma Financial Highlights 2011-2015 ($/m)
Table 4.1.2 Sun Pharma Geographical Revenue Mix FY2015
Table 4.1.3 Sun Pharma SWOT Analysis
Table 4.1.4 Sun Pharma's R&D Spending 2011-2015 ($/m & %)
Table 4.1.5 Sun Pharma Pharma's ANDA Approvals, in the US, to March 2015
Table 4.1.6 Sun Pharma's US & India Revenue FY2011-2015 ($/m & %)
Table 4.1.7 Key Sun / Ranbaxy Partnerships 2011-2015
Table 4.1.8 Key Sun / Ranbaxy M&A /JV Activity
Table 4.2.1 Dr Reddy's Financial Highlights 2011-2015 ($/ %)
Table 4.2.2 Dr Reddy's Geographical Revenue Mix FY2015 ($)
Table 4.2.3 Dr Reddy SWOT Analysis
Table 4.2.4 Dr Reddy's Key Acquisitions / Partnerships 2005-2015
Table 4.2.5 Dr Reddy's Geographical Generic Sales Revenue FY2015
Table 4.2.6 Dr Reddy's Gross Revenue Vs R&D Spending 2011-2015 ($/ %)
Table 4.3.1 Lupin Financial Highlights 2011-2015 ($/m)
Table 4.3.2 Lupin's US Generic Sales Revenue 2011-2015 ($/m)
Table 4.3.3 Lupin Revenue Geographical Mix FY2015 ($/m)
Table 4.3.4 Lupin R&D Spending 2011-2015 ($/m & %)
Table 4.3.5 Lupin SWOT Analysis
Table 4.3.6 Lupin ROW Revenue Breakdown FY2015 ($/m)
Table 4.3.7 Lupin Key Acquisitions / JVs 2011-2015
Table 4.3.8 Lupin's US Generics Revenues 2011-2015 ($/m)
Table 4.3.9 Lupin's Japan Revenues 2011-2015 ($/m)
Table 4.4.1 Cipla Financial Highlights 2011-2015 ($/m)
Table 4.4.2 Cipla Geographical Revenue Mix FY2014 ($/m)
Table 4.4.3 Cipla SWOT Analysis
Table 4.4.4 Cipla's Global JVs/Acquisitions 2013-2015
Table 4.4.5 R&D Spending 2011-2015 ($/m & %)
Table 4.5.1 Cadila Financial Highlights 2011-2015 ($/m)
Table 4.5.2 Cadila Revenue Geographical Mix FY2015 ($/m)
Table 4.5.3 Cadila SWOT Analysis
Table 4.5.4 Cadila Revenue US, India & Others FY2015 ($/m)
Table 4.5.5 Cadila Therapeutic Area of Branded Formulation Sales, India, FY2015 ($/m & %)
Table 4.5.6 Key JV /Alliances Zydus Cadila 2010-2015
Table 4.5.7 Cadila's R&D Spending 2011-2015 ($/m & %)
Table 4.6.1 Aurobindo Financial Highlights 2011-2015 ($/m)
Table 4.6.2 Aurobindo Revenue Breakdown by Geographical Area 2015 ($/m & %)
Table 4.6.3 Aurobindo Revenue Breakdown, by Product Area, 2015 ($/m & %)
Table 4.6.4 Aurobindo SWOT Analysis
Table 4.6.5 Key Contracts for Aurobindo 2009-2014 ($/m)
Table 4.6.6 Aurobindo Revenue breakdown by Geographical Area, 2015, ($/m & %)
Table 4.6.7 Aurobindo Revenue breakdown by Geographical Area 2015 ($/m & %)
Table 4.6.8 Aurobindo R&D Spending 2011-2015 ($/m & %)
Table 4.6.9 Aurobindo Drug Filings Fy2015 & Cumulative Historical Total
Table 4.6.10 Aurobindo FY2015 US FDA Drug Approvals
Table 4.7.1 Glenmark Financial Highlights 2011-2015 ($/m)
Table 4.7.2 Glenmark SWOT Analysis
Table 4.7.3 Glenmark R&D Spending 2011-2015 ($/m & %)
Table 4.7.4 Glenmark Geographical Revenue Mix FY2014 ($/m)
Table 4.7.5 Glenmark Global Revenue Breakdown FY2014 & FY2015 ($/m & %)
Table 4.8.1 Jubilant Financial Highlights 2011-2015 ($/m)
Table 4.8.2 Jubilant Geographical Revenue Mix FY2015 ($/m & %)
Table 4.8.3 Jubilant SWOT Analysis
Table 4.8.4 Jubilant R&D Spending 2011-2015 ($/m & %)
Table 4.8.5 Jubilant Subsidiary Activity
Table 4.8.6 Jubilant Key Recent Collaboration Activity
Table 4.9.1 Torrent Financial Highlights 2011-2015 ($/m)
Table 4.9.2 Torrent Revenue Breakdown by Geographical Area FY2015 ($/m & %)
Table 4.9.3 Torrent SWOT Analysis
Table 4.9.4 Torrent Geographical Revenue Mix FY2015 ($/m & %)
Table 4.9.5 Torrent R&D Spending 2011-2015 ($/m & %)
Table 4.9.6 Torrent's Global Revenue FY2014-FY2015 ($/m & %)
Table 4.10.1 Wockhardt Financial Highlights 2011-2015 ($/m)
Table 4.10.2 Wockhardt SWOT Analysis
Table 4.10.3 Wockhardt R&D Spending 2011-2015 ($/m & %)
Table 4.10.4 Wockhardt Geographical Revenue Mix FY2015
Table 4.10.5 Wockhardt's US Revenue Vs Total Global Revenue FY2011-FY2015 ($/m & %)

List of Figures

Figure 1.1 Forecast of Public Vs Private Healthcare Spending, India 2005 -2020 ($/bn)
Figure 2.1 Evolution of the India Pharmaceutical Sector 1970-2010
Figure 2.2 Rural v/s Urban Split of Indian Population
Figure 3.1 Pharmaceutical Market Revenue India 2004-2014
Figure 3.2 Export Revenue, by Region, 2011 (%)
Figure 3.3 Export Revenue, by Region, 2015 (%)
Figure 3.4 Export Revenue, by Region, 2011-2015 ($/bn P/A)
Figure 3.5 Indian Pharmaceutical Market - Products Market Share 2015 (%)
Figure 4.0.1 Top 10 Indian Pharmaceutical Companies, Domestic & Foreign Revenue FY2015 ($/m)
Figure 4.0.2 Top 10 Indian Pharmaceutical Companies R&D Spending, FY2015 ($/m)
Figure 4.1.1 Financial Highlights 2011-2015 ($/m)
Figure 4.1.2 Revenue Geographical Mix FY2015
Figure 4.2.1 Dr Reddy's Financial Highlights 2011-2015 ($/m)
Figure 4.2.2 Dr Reddy's Geographical Revenue Mix FY2015
Figure 4.2.3 Dr Reddy's Generic Sales Revenue, by Geography FY2015
Figure 4.2.4 India's Total Volume Share of US Generics Market 2006-2013 (%)
Figure 4.3.1 Lupin Financial Highlights 2011-2015 ($/m)
Figure 4.3.2 Lupin Revenue, by Geography, FY2015
Figure 4.3.3 Lupin ROW Revenue Breakdown FY2015
Figure 4.4.1 Cipla's Financial Highlights 2011-2015 ($/m)
Figure 4.4.2 Cipla Revenue, by Geography, FY2014
Figure 4.5.1 Cadila Financial Highlights 2011-2015 ($/m)
Figure 4.5.2 Cadila Formulations Revenue, by Geography FY2015
Figure 4.6.1 Aurobindo Financial Highlights 2011-2015 ($/m)
Figure 4.6.2 Aurobindo Revenue, by Geographical Area, FY2015 (%)
Figure 4.6.3 Aurobindo Revenue Breakdown, by Product Area, FY2015 (%)
Figure 4.6.4 Aurobindo Revenue, by Geographical Area, FY2015 (%)
Figure 4.7.1 Glenmark Financial Highlights 2011-2015 ($/m)
Figure 4.7.2 Glenmark Revenue, by Geography, FY2014 (%)
Figure 4.8.1 Jubilant Financial Highlights 2011-2015 ($/m)
Figure 4.8.2 Jubilant Revenue, by Geography, FY2015 (%)
Figure 4.9.1 Torrent Financial Highlights 2011-2015 ($/m)
Figure 4.9.2 Torrent Revenue, by Geography, FY2015 (%)
Figure 4.10.1 Wockhardt Financial Highlights 2011-2015 ($/m)
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs